ONCY
Oncolytics Biotech Inc.
NASDAQ · Healthcare · Biotechnology · CA
$0.84
−1.55%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -31.1%
- EBIT
- -29.7%
- EPS
- +6.2%
- Free cash flow
- -24.6%
- Operating cash flow
- -24.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +21.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -12.6%
- EBIT
- -12.5%
- Net income
- -26.2%
- EPS
- -36.7%
- Free cash flow
- -0.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026